CHST1 Drives Immunotherapy Resistance in Triple‐Negative Breast Cancer by Orchestrating an Immunosuppressive Microenvironment via the NKRF–CCL20–Macrophage Axis
TL;DR
Mechanical analyses support a CHST1–NKRF–CCL20 regulatory model and identifies CCR6 blockade as a potential therapeutic strategy and a CHST1–NKRF–CCL20 expression signature showed potential value for stratifying immunotherapy response.
Abstract
ABSTRACT Triple‐negative breast cancer (TNBC) derives limited benefit from immune checkpoint blockade, largely owing to primary resistance shaped by the tumor immune microenvironment. Here, baseline transcriptomic profiling of a neoadjuvant chemoimmunotherapy cohort identified carbohydrate sulfotransferase 1 (CHST1) as a candidate resistance‐associated gene. High CHST1 expression was associated with poor immunotherapy response and inferior clinical outcome across clinical datasets. Functionally, CHST1/Chst1 had minimal effects on tumor‐cell‐intrinsic proliferation, migration, or invasion in vitro, but promoted tumor growth in an immune context–dependent manner in vivo. Mechanistic analyses support a model in which CHST1 associates with NF‐κB‐repressing factor (NKRF) and limits its nuclear accumulation, a localization change associated with increased NF‐κB‐related CCL20 expression. Tumor‐cell CCL20 perturbation and rescue experiments further supported a functional contribution of CCL20 to macrophage recruitment and M2‐like remodeling. Pharmacologic CCR6 blockade enhanced the antitumor activity of anti–PD‐1 therapy in syngeneic TNBC models. Finally, a CHST1–NKRF–CCL20 expression signature showed potential value for stratifying immunotherapy response. Collectively, this study supports a CHST1–NKRF–CCL20 regulatory model and identifies CCR6 blockade as a potential therapeutic strategy.